ABIGAIL GUZMAN: Open Payments
NPI 1962127795 · REDLANDS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,796 in 145 payments from 13 companies in 2025. Trend: 2023 $1,287 · 2024 $2,428 · 2025 $2,796
Food & beverage: $2,796
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 37 | $875 |
| Otsuka America Pharmaceutical, Inc. | 23 | $447 |
| ABBVIE INC. | 17 | $319 |
| Vanda Pharmaceuticals Inc. | 12 | $290 |
| Alkermes, Inc. | 16 | $207 |
| Teva Pharmaceuticals USA, Inc. | 11 | $189 |
| E.R. Squibb & Sons, L.L.C. | 12 | $155 |
| Janssen Pharmaceuticals, Inc | 8 | $135 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $92 |
| Lundbeck LLC | 2 | $37 |
Products named: INGREZZA, REXULTI, VRAYLAR, ARISTADA, FANAPT, COBENFY, HETLIOZ, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
